Post-traumatic stress disorder

Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights 

Retrieved on: 
Thursday, February 29, 2024

Research and development (R&D) expenses were $87.5 million for the year ended December 31, 2023, compared with $65.1 million during the same period in 2022.

Key Points: 
  • Research and development (R&D) expenses were $87.5 million for the year ended December 31, 2023, compared with $65.1 million during the same period in 2022.
  • The Compass Pathways management team will host a conference call at 8.00am ET (1:00pm UK) on February 29, 2024.
  • A live webcast of the call will be available on Compass Pathway’s website at: Fourth Quarter 2023 Financial Results .
  • The call will also be webcast on the Compass Pathways website and archived for 30 days.

Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD

Retrieved on: 
Wednesday, February 28, 2024

SARASOTA, FL, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced positive results from its non-GLP small animal dose-ranging study of SPC-15, an intranasal prophylactic treatment for anxiety and post-traumatic stress disorder (PTSD).

Key Points: 
  • The purpose of the non-GLP small animal study was to identify the maximum tolerated intranasal dose of the drug pharmacokinetic and determine the therapeutically relevant dose range to be studied in clinical trials.
  • Data analysis demonstrated rapid absorption of SPC-15 with good exposure over a 24-hour period, suggesting a once-per-day human intranasal dosing regimen would be optimal.
  • “Non-GLP and GLP toxicology and safety pharmacology studies are required steps before seeking approval for our first-in-human clinical-stage trials of SPC-15,” said Eric Weisblum, CEO of Silo.
  • This is an exciting step forward for our Company as we advance our lead therapeutic, SPC-15.”

Healis Therapeutics' asset CKDB-501A shares Phase III topline results for glabellar injections from CKD Bio in South Korea

Retrieved on: 
Tuesday, February 27, 2024

The study results demonstrated that CKDB-501A is non-inferior compared to the active-controlled BOTOX® by AbbVie (NYSE: ABBV) in improving moderate-to-severe glabellar lines.

Key Points: 
  • The study results demonstrated that CKDB-501A is non-inferior compared to the active-controlled BOTOX® by AbbVie (NYSE: ABBV) in improving moderate-to-severe glabellar lines.
  • A randomized, double-blind, active-controlled, multi-center Phase 3 trial to investigate the efficacy and safety of CKDB-501A in subjects with moderate-to-severe glabellar lines was completed in South Korea on November 20, 2023 (NCT05804656).
  • “This is clinically promising to see Healis’ lead protein, CKDB-501A, pass safety and efficacy in South Korea,” said Dr. Eric Finzi, Co-Founder of Healis Therapeutics.
  • Healis Therapeutics announced a strategic partnership with CKD Bio in 2024 to develop CKDB-501A for CNS indications.

Cognosos Unveils Campus-Wide Staff Safety and Duress Solution Amid Escalating Cases of Workplace Violence in Hospitals and Healthcare Facilities

Retrieved on: 
Thursday, March 7, 2024

Research indicates that 40% of healthcare workers were exposed to workplace violence in the last two years.

Key Points: 
  • Research indicates that 40% of healthcare workers were exposed to workplace violence in the last two years.
  • Today, Cognosos–a leading provider of AI-enabled, real-time asset location solutions –announced the launch of Cognosos Protect™ to help hospitals more effectively protect staff from increasing instances of workplace violence.
  • “Empowering hospitals with a campus-wide security solution is the first step toward fostering a culture of safety.
  • “Traditional staff duress solutions come with inefficient and slow-to-install infrastructure, as well as hefty price tags,” continued Jarratt.

Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.

Retrieved on: 
Tuesday, February 27, 2024

The term sheet sets forth the principal terms of a mutual release and settlement agreement to be entered into by the Company and the Plaintiffs.

Key Points: 
  • The term sheet sets forth the principal terms of a mutual release and settlement agreement to be entered into by the Company and the Plaintiffs.
  • However, if the parties fail to do so by or before March 1, 2024, the term sheet will become binding.
  • Plaintiff’s release of Virpax is conditioned upon Virpax making its initial payment.
  • “I am pleased that we were able to bring this litigation to a satisfactory conclusion,” stated Gerald Bruce, CEO of Virpax Pharmaceuticals.

Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price

Retrieved on: 
Tuesday, February 27, 2024

The new CUSIP number for the Common Stock following the reverse split will be 928251206.

Key Points: 
  • The new CUSIP number for the Common Stock following the reverse split will be 928251206.
  • We believe this reverse split will allow us to regain compliance with Nasdaq’s minimum bid price requirement and to make our bid price more attractive to a broader universe of investors.
  • Stockholders whose shares are held in brokerage accounts should direct any questions concerning the reverse stock split to their broker.
  • The Nasdaq Capital Market requires, among other things, that a listed company’s common stock maintain a minimum bid price of at least $1.00 per share.

Wounded Warrior Project Urges Congress to Pass Comprehensive Veterans Agenda

Retrieved on: 
Wednesday, March 6, 2024

WASHINGTON, March 6, 2024 /PRNewswire/ -- Wounded Warrior Project® (WWP) CEO Lt. Gen. (Ret.) Mike Linnington today called on Congress to pass a series of bills focusing on mental health, financial wellness, and access to care that would comprehensively address the needs and well-being of wounded veterans who served after 9/11.

Key Points: 
  • Warriors On Capitol Hill This Week Advocating for Mental Health, Financial Wellness, and Access to Care
    WASHINGTON, March 6, 2024 /PRNewswire/ -- Wounded Warrior Project® (WWP) CEO Lt. Gen.
  • Mike Linnington today called on Congress to pass a series of bills focusing on mental health, financial wellness, and access to care that would comprehensively address the needs and well-being of wounded veterans who served after 9/11.
  • Congress hears from many organizations about many different issues, but our lawmakers need to ensure our country makes good on the promises we make to our veterans."
  • WWP will continue to serve the post-9/11 generation of injured veterans and will work with elected leaders, policymakers, and the warrior community to support our nation's heroes.

Purina Invests More Than $30 Million in Supporting Pets, People and the Planet

Retrieved on: 
Wednesday, February 28, 2024

ST. LOUIS, Feb. 28, 2024 /PRNewswire/ -- Nestlé Purina PetCare Company's belief that pets and people are better together was demonstrated throughout 2023 with investments of more than $30 million to support programs that aim to bring and keep people and pets together and forge partnerships that help communities and the environment thrive. In addition to providing funding, collaboration, and Purina pet food and cat litter donations, the company's 10,000 associates took an active role in their communities by volunteering nearly 5,000 hours in support of nonprofits last year.

Key Points: 
  • In 2023, Petfinder leveraged data and insights to help match an estimated 1.5 million pets with new families.
  • To help meet the increasing demand for therapy dogs, Purina is helping place more trained service and therapy dogs in schools and pediatric hospitals.
  • Each May, associates are encouraged to take time away from work to volunteer in their communities for Purina Cares Day.
  • Purina also made more than 20 grants surpassing $1 million to support capital and capacity building projects for local nonprofits in its communities.

MycoMeditations Surveys Show Lasting Benefits of Psilocybin Therapy for Major Depression and Anxiety Disorders

Retrieved on: 
Tuesday, February 20, 2024

TREASURE BEACH, Jamaica, Feb. 20, 2024 /PRNewswire-PRWeb/ -- MycoMeditations, a pioneer in legal psilocybin-assisted therapy retreats, today announced the results of two years of longitudinal (long-term) client surveys exploring the impact of its psilocybin retreats on individuals suffering with Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), and Social Anxiety Disorder (SAD). The findings complement MycoMeditations' previously released surveys focused on Post-Traumatic Stress Disorder (PTSD).

Key Points: 
  • The findings complement MycoMeditations' previously released surveys focused on Post-Traumatic Stress Disorder (PTSD).
  • MycoMeditations employed the PHQ-9, GAD-7, and SM-SAD-Adult questionnaires to measure self-reported symptom severity and long-term outcomes across MDD, GAD, and SAD, respectively.
  • Clinically significant improvements were maintained for one year following retreat for each Major Depressive Disorder, Generalized Anxiety, and Social Anxiety, suggesting possible long-term efficacy of psilocybin-assisted therapy.
  • The data suggests the viability of multiple psilocybin treatments in a short period of time when coupled with therapy, as MycoMeditations retreats are 7-nights with 3 psilocybin sessions on alternating days.

Orlando Health and Acadia Healthcare Hold Groundbreaking Ceremony for New Behavioral Health Hospital to Serve Greater Orlando Area

Retrieved on: 
Thursday, February 15, 2024

Orlando Health and Acadia Healthcare today held a ceremony to celebrate the start of construction on a previously announced 144-bed behavioral health hospital that will expand access to critical mental health services in the Orlando metro area.

Key Points: 
  • Orlando Health and Acadia Healthcare today held a ceremony to celebrate the start of construction on a previously announced 144-bed behavioral health hospital that will expand access to critical mental health services in the Orlando metro area.
  • View the full release here: https://www.businesswire.com/news/home/20240215860586/en/
    Orlando Health and Acadia Healthcare Break Ground on Construction of a New Behavioral Health Hospital in Apopka, Florida, with an anticipated opening in Spring 2025.
  • “This hospital will expand Orlando Health’s existing capabilities and provide greater access to life-saving behavioral health services,” Chris Hunter, Chief Executive Officer of Acadia Healthcare.
  • This hospital will extend Orlando Health’s legacy of providing quality behavioral health services to their patients.”
    Once the new hospital is fully operational, Orlando Health will transfer all inpatient behavioral health services from its South Seminole Hospital Campus.